Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.

In allogeneic hematopoietic cell transplantation (allo-HCT), the immune recognition of host antigens by donor T lymphocytes leads to a beneficial graft-versus-leukemia (GvL) effect as well as to life-threatening graft-versus-host disease (GvHD). Genetic modification of T lymphocytes with a retroviral vector (RV) expressing the herpes simplex virus-thymidine kinase (TK) suicide gene confers selective sensitivity to the prodrug ganciclovir (GCV). In patients, the infusion of TK+ lymphocytes and the subsequent administration of GCV resulted in a time-wise modulation of antihost reactivity for a GvL effect, while controlling GvHD. Because activation required for genetic modification with RV may reduce antihost reactivity, we investigated the requirements for maximizing the potency of human TK+ lymphocytes. Whereas T-cell receptor triggering alone led to effector memory (EM) TK+ lymphocytes, the addition of CD28 costimulation through cell-sized beads resulted in the generation of central memory (CM) TK+ lymphocytes. In a quantitative model for GvHD using nonobese diabetic/severely combined immunodeficient mice, CM TK+ lymphocytes were more potent than EM TK+ lymphocytes. GCV administration efficiently controlled GvHD induced by CM TK+ lymphocytes. These results warrant the clinical investigation of CM suicide gene-modified human T lymphocytes for safe and effective allo-HCT.

[1]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[2]  Jiang Zhu,et al.  Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[3]  N. Kröger,et al.  Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. , 2004, Blood.

[4]  S. Alexander,et al.  Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. , 2004, Blood.

[5]  J. Buckner,et al.  Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.

[6]  E. Robinet,et al.  Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. , 2004, Stem cells and development.

[7]  M. Brenner,et al.  Genetic modification of T lymphocytes for adoptive immunotherapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[9]  A. Balas,et al.  Functional and phenotypic variations in human T cells subjected to retroviral-mediated gene transfer , 2004, Gene Therapy.

[10]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[11]  A. Dejean,et al.  Alloreactive CD4 T lymphocytes responsible for acute and chronic graft‐versus‐host disease are contained within the CD45RChigh but not the CD45RClow subset , 2004, European journal of immunology.

[12]  D. Klatzmann,et al.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. , 2003, The Journal of clinical investigation.

[13]  A. Hagenbeek,et al.  A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. , 2003, Blood.

[14]  P. Corthésy,et al.  Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. , 2003, Blood.

[15]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[16]  L. Naldini,et al.  Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. , 2003, Blood.

[17]  M. Shlomchik,et al.  Memory CD4+ T cells do not induce graft-versus-host disease. , 2003, The Journal of clinical investigation.

[18]  R. Korngold,et al.  Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses , 2003 .

[19]  A. Hagenbeek,et al.  Safety of retroviral gene marking with a truncated NGF receptor , 2003, Nature Medicine.

[20]  Antonio Lanzavecchia,et al.  T cell fitness determined by signal strength , 2003, Nature Immunology.

[21]  J. Gorski,et al.  Elimination of Leukemia in the Absence of Lethal Graft-Versus-Host Disease After Allogenic Bone Marrow Transplantation , 2003, The Journal of Immunology.

[22]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[23]  S. Riddell,et al.  Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. , 2003, Blood.

[24]  S. Heimfeld,et al.  CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. , 2003, Blood.

[25]  D. Klatzmann,et al.  Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. , 2002, Blood.

[26]  B. Falini,et al.  Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice , 2002, Cancer Gene Therapy.

[27]  A. Fischer,et al.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study , 2002, The Lancet.

[28]  J. Wagner,et al.  Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. , 2002, Human gene therapy.

[29]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[30]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[31]  C. Ricordi,et al.  PATTERNS OF ENGRAFTMENT IN DIFFERENT STRAINS OF IMMUNODEFICIENT MICE RECONSTITUTED WITH HUMAN PERIPHERAL BLOOD LYMPHOCYTES1 , 2001, Transplantation.

[32]  C. Perreault,et al.  Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease , 2001, Nature Medicine.

[33]  J. Crawford,et al.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. , 2001, The Journal of clinical investigation.

[34]  F. Appelbaum,et al.  Haematopoietic cell transplantation as immunotherapy , 2001, Nature.

[35]  A. Lanzavecchia,et al.  Migration and Function of Antigen-Primed Nonpolarized T Lymphocytes in Vivo , 2001, The Journal of experimental medicine.

[36]  G. Sandford,et al.  Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. , 2001, Blood.

[37]  S. Kornblau,et al.  Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. , 2001, Cancer research.

[38]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[39]  C. Springer,et al.  Prodrug-activating systems in suicide gene therapy. , 2000, The Journal of clinical investigation.

[40]  J. Ledbetter,et al.  IL-2 and IL-15 Regulate CD154 Expression on Activated CD4 T Cells1 , 2000, The Journal of Immunology.

[41]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[42]  S. Depraetere,et al.  Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice , 2000, Clinical and experimental immunology.

[43]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[44]  D. Klatzmann,et al.  Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? , 1999, Immunology today.

[45]  A. Lanzavecchia,et al.  T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.

[46]  M. Davis,et al.  A receptor/cytoskeletal movement triggered by costimulation during T cell activation. , 1998, Science.

[47]  C. Bordignon,et al.  Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. , 1998, Human gene therapy.

[48]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[49]  K. Ozker,et al.  Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. , 1998, Journal of immunology.

[50]  Craig W. Reynolds,et al.  In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. , 1998, Transplantation.

[51]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[52]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[53]  M. Miyasaka,et al.  Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice , 1993, The Journal of experimental medicine.

[54]  F. Ciceri,et al.  Application of donor lymphocytes expressing a suicide gene for early GVL induction and later control of GVH reactions after bone-marrow transplantation. , 2005, Methods in molecular medicine.

[55]  H. Nakauchi,et al.  An in vivo assay for retrovirally transduced human peripheral T lymphocytes using nonobese diabetic/severe combined immunodeficiency mice. , 2005, Experimental hematology.

[56]  S. Rosenberg,et al.  Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. , 2005, Blood.

[57]  R. Korngold,et al.  Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.